{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T12:45:54Z","timestamp":1693745154677},"reference-count":113,"publisher":"Bentham Science Publishers Ltd.","issue":"12","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Given the importance of COVID-19-induced ARDS, recently, researchers have\nstrived to determine underlying mechanisms involved in the inflammatory responses. In\nthis regard, inflammasomes possess a distinct priority for cytokine storm occurrence and,\nsubsequently, ARDS progression in ill patients with SARS-CoV-2 infection. In this minireview,\nthe characteristics of known inflammasome inhibitors and designed research in\nthis field were concretely deciphered.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867329666220906111550","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T09:15:30Z","timestamp":1662455730000},"page":"1406-1419","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Putative Therapeutic Impact of Inflammasome Inhibitors against\nCOVID-19-Induced ARDS"],"prefix":"10.2174","volume":"30","author":[{"given":"Seyed Fazel","family":"Nabavi","sequence":"first","affiliation":[{"name":"Advanced Medical Pharma (BIOTEC), Benevento, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeleh","family":"Sahebnasagh","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Department of Internal\nMedicine, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahad","family":"Shahbazi","sequence":"additional","affiliation":[{"name":"Eye Research\nCenter, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Mohammad","family":"Nabavi","sequence":"additional","affiliation":[{"name":"Advanced Medical Pharma (BIOTEC), Benevento, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeid","family":"Azimi","sequence":"additional","affiliation":[{"name":"Student Research Committee,\nDepartment of Clinical Pharmacy, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences,\nTehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malihe Khayat","family":"Kashani","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Imam Khomeini Hospital, Tehran University of Medical\nSciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solomon","family":"Habtemariam","sequence":"additional","affiliation":[{"name":"Pharmacognosy Research Laboratories &amp; Herbal Analysis Services UK, University\nof Greenwich, Chatham-Maritime, Kent ME4 4TB, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mojde","family":"Rahmani","sequence":"additional","affiliation":[{"name":"Student Research Committee, Faculty of Pharmacy,\nShahid Sadoughi University of Medical Sciences, Yazd, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohadese","family":"Badiee","sequence":"additional","affiliation":[{"name":"Student Research Committee, Faculty of Pharmacy,\nShahid Sadoughi University of Medical Sciences, Yazd, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javad","family":"Hashemi","sequence":"additional","affiliation":[{"name":"Department of Pathobiology and Laboratory\nSciences, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Saghafi","sequence":"additional","affiliation":[{"name":"Department\nof Clinical Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Shahid Sadoughi\nUniversity of Medical Sciences, Yazd, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiumarth","family":"Amini","sequence":"additional","affiliation":[{"name":"Student Research Committee, Faculty of Pharmacy, Tehran\nUniversity of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Azimi","sequence":"additional","affiliation":[{"name":"Exceptional Talents Development Center, Scientific Research\nCenter, Tehran University of Medical Sciences, Tehran Heart Center, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aysa","family":"Rezabakhsh","sequence":"additional","affiliation":[{"name":"Hematology, Immune\nCell Therapy, and Stem Cells Transplantation Research Center, Clinical Research Institute, Urmia University\nof Medical Sciences, Urmia, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/jcpt.13251","volume":"45","author":"Sahebnasagh A.","year":"2020","unstructured":"Sahebnasagh A.; Saghafi F.; Safdari M.; Neutrophil elas-tase inhibitor (sivelestat), may be a promising therapeutic op-tion for management of acute lung injury\/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19. J Clin Pharm Ther 2020,45(6),1515-1519","journal-title":"J Clin Pharm Ther"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"14103","DOI":"10.1096\/fj.202001394RR","volume":"34","author":"Stilhano R.S.","year":"2020","unstructured":"Stilhano R.S.; Costa A.J.; Nishino M.S.; SARS-CoV-2 and the possible connection to ERs, ACE2 and RAGE: Fo-cus on susceptibility factors. FASEB J 2020,34(11),14103-14119","journal-title":"FASEB J"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.arcmed.2020.08.002","volume":"51","author":"Sahebnasagh A.","year":"2020","unstructured":"Sahebnasagh A.; Mojtahedzadeh M.; Najmeddin F.; A perspective on erythropoietin as a potential adjuvant therapy for acute lung injury\/acute respiratory distress syndrome in patients with COVID-19. Arch Med Res 2020,51(7),631-635","journal-title":"Arch Med Res"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1007\/s43440-020-00152-9","volume":"72","author":"Sahebnasagh A.","year":"2020","unstructured":"Sahebnasagh A.; Avan R.; Saghafi F.; Pharmacological treatments of COVID-19. Pharmacol Rep 2020,72(6),1446-1478","journal-title":"Pharmacol Rep"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.3389\/fimmu.2020.01708","volume":"11","author":"Tang Y.","year":"2020","unstructured":"Tang Y.; Liu J.; Zhang D.; Xu Z.; Ji J.; Wen C.; Cytokine storm in COVID-19: The current evidence and treatment strategies. Front Immunol 2020,11,1708","journal-title":"Front Immunol"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/jmv.25958","volume":"92","year":"2020","unstructured":"EL\u2010Arabey AA, Abdalla M. Metformin and COVID\u201019: A novel deal of an old drug. J Med Virol 2020,92(11),2293-2294","journal-title":"J Med Virol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1128\/CVI.00636-12","volume":"20","author":"D\u2019Elia R.V.","year":"2013","unstructured":"D\u2019Elia R.V.; Harrison K.; Oyston P.C.; Lukaszewski R.A.; Clark G.C.; Targeting the &#x201C;cytokine storm&#x201D; for therapeutic benefit. Clin Vaccine Immunol 2013,20(3),319-327","journal-title":"Clin Vaccine Immunol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00134-020-06059-6","volume":"46","author":"Leisman D.E.","year":"2020","unstructured":"Leisman D.E.; Deutschman C.S.; Legrand M.; Facing COVID-19 in the ICU: Vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med 2020,46(6),1105-1108","journal-title":"Intensive Care Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1016\/S2213-2600(20)30216-2","volume":"8","author":"Jose R.J.","year":"2020","unstructured":"Jose R.J.; Manuel A.; COVID-19 cytokine storm: The inter-play between inflammation and coagulation. Lancet Respir Med 2020,8(6),e46-e47","journal-title":"Lancet Respir Med"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"em202","DOI":"10.29333\/ejgm\/7850","volume":"17","author":"Abdulamir A.S.","year":"2020","unstructured":"Abdulamir A.S.; Hafidh R.R.; The possible immunological pathways for the variable immunopathogenesis of COVID-19 infections among healthy adults, elderly and children. Elect J General Med 2020,17(4),em202","journal-title":"Elect J General Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13045-019-0755-0","volume":"12","author":"Xu S.","year":"2019","unstructured":"Xu S.; Li X.; Liu Y.; Xia Y.; Chang R.; Zhang C.; Inflam-masome inhibitors: Promising therapeutic approaches against cancer. J Hematol Oncol 2019,12(1),64","journal-title":"J Hematol Oncol"},{"key":"ref=12","first-page":"1","volume":"7","author":"Ferreira A.C.","year":"2021","unstructured":"Ferreira A.C.; Soares V.C.; de Azevedo-Quintanilha I.G.; SARS-CoV-2 engages inflammasome and pyroptosis in hu-man primary monocytes. Cell Death Discov 2021,7(1),1-12","journal-title":"Cell Death Discov"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"e20201707","DOI":"10.1084\/jem.20201707","volume":"218","author":"Rodrigues T.S.","year":"2021","unstructured":"Rodrigues T.S.; de S&#xE1; K.S.G.; Ishimoto A.Y.; Inflam-masomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J Exp Med 2021,218(3),e20201707","journal-title":"J Exp Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13287-022-02820-4","volume":"13","author":"Rajabi H.","year":"2022","unstructured":"Rajabi H.; Konyalilar N.; Erkan S.; Emerging role of exosomes in the pathology of chronic obstructive pulmonary diseases; destructive and therapeutic properties. Stem Cell Res Ther 2022,13(1),144","journal-title":"Stem Cell Res Ther"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.3389\/fimmu.2020.01580","volume":"11","author":"van den Berg D.F.","year":"2020","unstructured":"van den Berg D.F.; te Velde A.A.; Severe COVID-19: NLRP3 inflammasome dysregulated. Front Immunol 2020,11,1580","journal-title":"Front Immunol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","volume":"20","author":"Merad M.","year":"2020","unstructured":"Merad M.; Martin J.C.; Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophag-es. Nat Rev Immunol 2020,20(6),355-362","journal-title":"Nat Rev Immunol"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"Mehta P.","year":"2020","unstructured":"Mehta P.; McAuley D.; Brown M.; COVID\u201019: Con-sider cytokine storm syndromes and immunosuppression. Lancet 2020,395(10229),1033","journal-title":"Lancet"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s12015-020-10108-4","volume":"17","author":"Bagheri H.S.","year":"2021","unstructured":"Bagheri H.S.; Karimipour M.; Heidarzadeh M.; Rajabi H.; Sokullu E.; Rahbarghazi R.; Does the global outbreak of COVID-19 or other viral diseases threaten the stem cell res-ervoir inside the body? Stem Cell Rev Rep 2021,17(1),214-230","journal-title":"Stem Cell Rev Rep"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/cbf.3720","volume":"40","author":"Rezabakhsh A.","year":"2022","unstructured":"Rezabakhsh A.; Mahdipour M.; Nourazarian A.; Appli-cation of exosomes for the alleviation of COVID-19-related pathologies. Cell Biochem Funct 2022,40(5),430-438","journal-title":"Cell Biochem Funct"},{"key":"ref=20","first-page":"112474","volume":"11","author":"Rivero V.J.C.","year":"2020","unstructured":"Rivero V.J.C.; Dietrich W.D.; Keane R.W.; The inflam-masome in times of COVID-19. Front Immunol 2020,11,112474","journal-title":"Front Immunol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s12967-018-1606-4","volume":"16","author":"Chen J.","year":"2018","unstructured":"Chen J.; Wang S.; Fu R.; RIP3 dependent NLRP3 in-flammasome activation is implicated in acute lung injury in mice. J Transl Med 2018,16(1),233","journal-title":"J Transl Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/BF01534377","volume":"19","author":"Patton L.M.","year":"1995","unstructured":"Patton L.M.; Saggart B.S.; Ahmed N.K.; Leff J.A.; Repine J.E.; Interleukin-1-induced neutrophil recruitment and acute lung injury in hamsters. Inflammation 1995,19(1),23-29","journal-title":"Inflammation"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.immuni.2009.02.006","volume":"30","author":"Thomas P.G.","year":"2009","unstructured":"Thomas P.G.; Dash P.; Aldridge J.R.; The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 2009,30(4),566-575","journal-title":"Immunity"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","volume":"126","author":"Abbate A.","year":"2020","unstructured":"Abbate A.; Toldo S.; Marchetti C.; Kron J.; Van Tassell B.W.; Dinarello C.A.; Interleukin-1 and the inflammasome as thera-peutic targets in cardiovascular disease. Circ Res 2020,126(9),1260-1280","journal-title":"Circ Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.3390\/ijms20133328","volume":"20","author":"Kelley N.","year":"2019","unstructured":"Kelley N.; Jeltema D.; Duan Y.; He Y.; The NLRP3 inflam-masome: An overview of mechanisms of activation and regu-lation. Int J Mol Sci 2019,20(13),3328","journal-title":"Int J Mol Sci"},{"key":"ref=26","first-page":"288","volume":"210","author":"He L.","year":"2006","unstructured":"He L.; Ding Y.; Zhang Q.; Expression of elevated levels of pro\u2010inflammatory cytokines in SARS\u2010CoV\u2010infected ACE2+ cells in SARS patients: Relation to the acute lung in-jury and pathogenesis of SARS. J Pathol Soc Great Britain and Ireland 2006,210(3),288-297","journal-title":"J Pathol Soc Great Britain and Ireland"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00011-020-01413-2","volume":"70","author":"Toldo S.","year":"2021","unstructured":"Toldo S.; Bussani R.; Nuzzi V.; Inflammasome formation in the lungs of patients with fatal COVID-19. Inflamm Res 2021,70(1),7-10","journal-title":"Inflamm Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1007\/s10753-018-0787-6","volume":"41","author":"Ulke-Lem&#xE9;e A.","year":"2018","unstructured":"Ulke-Lem&#xE9;e A.; Lau A.; Nelson M.C.; James M.T.; Muruve D.A.; MacDonald J.A.; Quantification of inflammasome adap-tor protein ASC in biological samples by multiple-reaction monitoring mass spectrometry. Inflammation 2018,41(4),1396-1408","journal-title":"Inflammation"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1128\/JVI.02667-12","volume":"87","author":"Kumar M.","year":"2013","unstructured":"Kumar M.; Roe K.; Orillo B.; Inflammasome adaptor protein Apoptosis-associated speck-like protein containing CARD (ASC) is critical for the immune response and sur-vival in west Nile virus encephalitis. J Virol 2013,87(7),3655-3667","journal-title":"J Virol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrmicro2820","volume":"10","author":"Nieva J.L.","year":"2012","unstructured":"Nieva J.L.; Madan V.; Carrasco L.; Viroporins: Structure and biological functions. Nat Rev Microbiol 2012,10(8),563-574","journal-title":"Nat Rev Microbiol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"e02325","DOI":"10.1128\/mBio.02325-17","volume":"9","author":"Casta&#xF1;o-Rodriguez C.","year":"2018","unstructured":"Casta&#xF1;o-Rodriguez C.; Honrubia J.M.; Guti&#xE9;rrez-&#xC1;lvarez J.; Role of severe acute respiratory syndrome coronavirus vi-roporins E, 3a, and 8a in replication and pathogenesis. MBio 2018,9(3),e02325-e17","journal-title":"MBio"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.3390\/v7072786","volume":"7","author":"Nieto-Torres J.","year":"2015","unstructured":"Nieto-Torres J.; Verdi&#xE1;-B&#xE1;guena C.; Casta&#xF1;o-Rodriguez C.; Aguilella V.; Enjuanes L.; Relevance of viroporin ion channel activity on viral replication and pathogenesis. Viruses 2015,7(7),3552-3573","journal-title":"Viruses"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1084\/jem.20172222","volume":"215","author":"Boucher D.","year":"2018","unstructured":"Boucher D.; Monteleone M.; Coll R.C.; Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflam-masome activity. J Exp Med 2018,215(3),827-840","journal-title":"J Exp Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"eaav1447","DOI":"10.1126\/sciimmunol.aav1447","volume":"4","author":"Lieberman J.","year":"2019","unstructured":"Lieberman J.; Wu H.; Kagan J.C.; Gasdermin D activity in inflammation and host defense. Sci Immunol 2019,4(39),eaav1447","journal-title":"Sci Immunol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nature02664","volume":"430","author":"Mariathasan S.","year":"2004","unstructured":"Mariathasan S.; Newton K.; Monack D.M.; Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 2004,430(6996),213-218","journal-title":"Nature"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1600-065X.2011.01044.x","volume":"243","author":"Miao E.A.","year":"2011","unstructured":"Miao E.A.; Rajan J.V.; Aderem A.; Caspase-1-induced pyrop-totic cell death. Immunol Rev 2011,243(1),206-214","journal-title":"Immunol Rev"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1038\/s41467-019-09753-2","volume":"10","author":"Tsuchiya K.","year":"2019","unstructured":"Tsuchiya K.; Nakajima S.; Hosojima S.; Caspase-1 initi-ates apoptosis in the absence of gasdermin D. Nat Commun 2019,10(1),2091","journal-title":"Nat Commun"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.it.2020.10.005","volume":"41","author":"Lee S.","year":"2020","unstructured":"Lee S.; Channappanavar R.; Kanneganti T-D.; Coronaviruses: Innate immunity, inflammasome activation, inflammatory cell death, and cytokines. Trends Immunol 2020,41(12),1083-1099","journal-title":"Trends Immunol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"e00291","DOI":"10.1002\/prp2.291","volume":"5","author":"Mandal A.K.","year":"2017","unstructured":"Mandal A.K.; Mercado A.; Foster A.; Zandi-Nejad K.; Mount D.B.; Uricosuric targets of tranilast. Pharmacol Res Perspect 2017,5(2),e00291-e1","journal-title":"Pharmacol Res Perspect"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"e8689","DOI":"10.15252\/emmm.201708689","volume":"10","author":"Huang Y.","year":"2018","unstructured":"Huang Y.; Jiang H.; Chen Y.; Tranilast directly targets NLRP 3 to treat inflammasome\u2010driven diseases. EMBO Mol Med 2018,10(4),e8689","journal-title":"EMBO Mol Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3389\/fcell.2020.00588","volume":"8","author":"Zhuang T.","year":"2020","unstructured":"Zhuang T.; Li S.; Yi X.; Tranilast directly targets NLRP3 to protect melanocytes from keratinocyte-derived IL-1&#x3B2; under oxidative stress. Front Cell Dev Biol 2020,8,588","journal-title":"Front Cell Dev Biol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.phrs.2014.10.009","volume":"91","author":"Darakhshan S.","year":"2015","unstructured":"Darakhshan S.; Pour A.B.; Tranilast: A review of its therapeu-tic applications. Pharmacol Res 2015,91,15-28","journal-title":"Pharmacol Res"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41420-020-0245-8","volume":"6","author":"Tsuji G.","year":"2020","unstructured":"Tsuji G.; Hashimoto-Hachiya A.; Yen V.H.; Metformin inhibits IL-1&#x3B2; secretion via impairment of NLRP3 inflam-masome in keratinocytes: Implications for preventing the de-velopment of psoriasis. Cell Death Discov 2020,6(1),11","journal-title":"Cell Death Discov"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.7150\/ijbs.29680","volume":"15","author":"Yang F.","year":"2019","unstructured":"Yang F.; Qin Y.; Wang Y.; Metformin inhibits the NLRP3 inflammasome via AMPK\/mTOR-dependent effects in diabetic cardiomyopathy. Int J Biol Sci 2019,15(5),1010-1019","journal-title":"Int J Biol Sci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"109410","DOI":"10.1016\/j.biopha.2019.109410","volume":"119","author":"Tang G.","year":"2019","unstructured":"Tang G.; Duan F.; Li W.; Metformin inhibited Nod-like receptor protein 3 inflammasomes activation and suppressed diabetes-accelerated atherosclerosis in apoE\u2212\/\u2212 mice. Biomed Pharmacother 2019,119,109410","journal-title":"Biomed Pharmacother"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"104763","DOI":"10.1016\/j.archoralbio.2020.104763","volume":"116","author":"Zhou X.","year":"2020","unstructured":"Zhou X.; Wang Q.; Nie L.; Metformin ameliorates the NLPP3 inflammasome mediated pyroptosis by inhibiting the expression of NEK7 in diabetic periodontitis. Arch Oral Biol 2020,116,104763","journal-title":"Arch Oral Biol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"e2975","DOI":"10.1002\/dmrr.2975","volume":"34","author":"Malik F.","year":"2018","unstructured":"Malik F.; Mehdi S.F.; Ali H.; Is metformin poised for a second career as an antimicrobial? Diabetes Metab Res Rev 2018,34(4),e2975","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=48","first-page":"363","volume":"21","author":"Ismail Hassan F.","year":"2020","unstructured":"Ismail Hassan F.; Didari T.; Khan F.; Niaz K.; Mojtahedzadeh M.; Abdollahi M.; A review on the protective effects of met-formin in sepsis-induced organ failure. Cell J 2020,21(4),363-370","journal-title":"Cell J"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/nature12051","volume":"496","author":"Paddon C.J.","year":"2013","unstructured":"Paddon C.J.; Westfall P.J.; Pitera D.J.; High-level semi-synthetic production of the potent antimalarial artemisinin. Nature 2013,496(7446),528-532","journal-title":"Nature"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMe2020388","volume":"383","author":"Cohen M.S.","year":"2020","unstructured":"Cohen M.S.; Hydroxychloroquine for the prevention of COVID-19-searching for evidence. Mass Medical Soc 2020,383,585-586","journal-title":"Mass Medical Soc"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"105945","DOI":"10.1016\/j.ijantimicag.2020.105945","volume":"55","author":"Sahraei Z.","year":"2020","unstructured":"Sahraei Z.; Shabani M.; Shokouhi S.; Saffaei A.; Aminoquino-lines against coronavirus disease 2019 (COVID-19): Chlo-roquine or hydroxychloroquine. Int J Antimicrob Agents 2020,55(4),105945","journal-title":"Int J Antimicrob Agents"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"113619","DOI":"10.1016\/j.bcp.2019.08.021","volume":"169","author":"Bai L.","year":"2019","unstructured":"Bai L.; Li J.; Li H.; Renoprotective effects of artemisinin and hydroxychloroquine combination therapy on IgA nephropathy via suppressing NF-&#x3BA;B signaling and NLRP3 inflammasome activation by exosomes in rats. Biochem Pharmacol 2019,169,113619","journal-title":"Biochem Pharmacol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41419-018-0378-3","volume":"9","author":"Tang T.T.","year":"2018","unstructured":"Tang T.T.; Lv L.L.; Pan M.M.; Hydroxychloroquine atten-uates renal ischemia\/reperfusion injury by inhibiting cathep-sin mediated NLRP3 inflammasome activation. Cell Death Dis 2018,9(3),351","journal-title":"Cell Death Dis"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"Schroeder M.E.","year":"2017","unstructured":"Schroeder M.E.; Russo S.; Costa C.; Pro-inflammatory Ca++-activated K+ channels are inhibited by hydroxychloro-quine. Sci Rep 2017,7(1),1-7","journal-title":"Sci Rep"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa2016638","volume":"383","author":"Boulware D.R.","year":"2020","unstructured":"Boulware D.R.; Pullen M.F.; Bangdiwala A.S.; A Ran-domized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19. N Engl J Med 2020,383(6),517-525","journal-title":"N Engl J Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"2020.07.15.20151852","DOI":"10.1101\/2020.07.15.20151852","author":"Horby P.","year":"2020","unstructured":"Horby P.; Mafham M.; Linsell L.; Effect of hydroxychlo-roquine in hospitalized patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. Medrxiv 2020,2020.07.15.20151852","journal-title":"Medrxiv"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"623","DOI":"10.7326\/M20-4207","volume":"173","author":"Skipper C.P.","year":"2020","unstructured":"Skipper C.P.; Pastick K.A.; Engen N.W.; Hydroxychloro-quine in nonhospitalized adults with early COVID-19: A randomized trial. Ann Intern Med 2020,173(8),623-631","journal-title":"Ann Intern Med"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2020.06.19.159053","DOI":"10.1101\/2020.06.19.159053","author":"Kaptein S.J.","year":"2020","unstructured":"Kaptein S.J.; Jacobs S.; Langendries L.; Antiviral treat-ment of SARS-CoV-2-infected hamsters reveals a weak ef-fect of favipiravir and a complete lack of effect for hy-droxychloroquine. BioRxiv 2020,2020.06.19.159053","journal-title":"BioRxiv"},{"key":"ref=59","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-27223\/v1","author":"Maisonnasse P.","year":"2020","unstructured":"Maisonnasse P.; Guedj J.; Contreras V.; Hydroxychloro-quine in the treatment and prophylaxis of SARS-CoV-2 in-fection in non-human primates. Research Square 2020","journal-title":"Research Square"},{"key":"ref=60","volume":"2017","author":"Chen X","year":"2017","unstructured":"Chen X; Wang N; Zhu Y; The antimalarial chloroquine suppresses LPS-induced NLRP3 inflammasome activation and confers protection against murine endotoxic shock. Mediators of Inflam 2017,2017"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jcrc.2020.03.005","volume":"57","author":"Cortegiani A.","year":"2020","unstructured":"Cortegiani A.; Ingoglia G.; Ippolito M.; A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020,57,279-283","journal-title":"J Crit Care"},{"key":"ref=62","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4312519","volume":"2020","author":"Ayele Mega T","year":"2020","unstructured":"Ayele Mega T; Feyissa TM; Dessalegn Bosho D; The outcome of hydroxychloroquine in patients treated for COVID-19: Systematic review and meta-analysis.  Can Respir J 2020,2020","journal-title":"Can Respir J"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/S0008-6363(00)00146-2","volume":"47","author":"Koh K.","year":"2000","unstructured":"Koh K.; Effects of statins on vascular wall: Vasomotor func-tion, inflammation, and plaque stability. Cardiovasc Res 2000,47(4),648-657","journal-title":"Cardiovasc Res"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.amjcard.2006.09.125","volume":"99","author":"Forrester J.S.","year":"2007","unstructured":"Forrester J.S.; Libby P.; The inflammation hypothesis and its potential relevance to statin therapy. Am J Cardiol 2007,99(5),732-738","journal-title":"Am J Cardiol"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.immuni.2018.08.021","volume":"49","author":"Guo C","year":"2018","unstructured":"Guo C; Chi Z; Jiang D; Cholesterol homeostatic regulator SCAP-SREBP2 integrates NLRP3 inflammasome activation and cholesterol biosynthetic signaling in macrophages. Immunity 2018,49(5),842-56. e7","journal-title":"Immunity"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1042\/CS20130043","volume":"126","author":"Satoh M.","year":"2014","unstructured":"Satoh M.; Tabuchi T.; Itoh T.; Nakamura M.; NLRP3 inflam-masome activation in coronary artery disease: Results from prospective and randomized study of treatment with atorvas-tatin or rosuvastatin. Clin Sci (Lond) 2014,126(3),233-241","journal-title":"Clin Sci (Lond)"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/MCA.0000000000000255","volume":"26","author":"Altaf A.","year":"2015","unstructured":"Altaf A.; Qu P.; Zhao Y.; Wang H.; Lou D.; Niu N.; NLRP3 inflammasome in peripheral blood monocytes of acute coro-nary syndrome patients and its relationship with statins. Coron Artery Dis 2015,26(5),409-421","journal-title":"Coron Artery Dis"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1097\/CCM.0000000000003816","volume":"47","author":"Rogers A.J.","year":"2019","unstructured":"Rogers A.J.; Guan J.; Trtchounian A.; Association of elevated plasma interleukin 18 level with increased mortality in a clinical trial of statin treatment for ards. Crit Care Med 2019,47(8),1089","journal-title":"Crit Care Med"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.1111\/bph.15166","volume":"177","author":"Rodrigues-Diez R.R.","year":"2020","unstructured":"Rodrigues-Diez R.R.; Tejera-Mu&#xF1;oz A.; Marquez-Exposito L.; Statins: Could an old friend help in the fight against COVID\u201019? Br J Pharmacol 2020,177(21),4873-4886","journal-title":"Br J Pharmacol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1001\/archinternmed.2009.286","volume":"169","author":"Tleyjeh I.M.","year":"2009","unstructured":"Tleyjeh I.M.; Kashour T.; Hakim F.A.; Statins for the prevention and treatment of infections: A systematic review and meta-analysis. Arch Intern Med 2009,169(18),1658-1667","journal-title":"Arch Intern Med"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3389\/fimmu.2017.00873","volume":"8","author":"Kopitar-Jerala N.","year":"2017","unstructured":"Kopitar-Jerala N.; The role of interferons in inflammation and inflammasome activation. Front Immunol 2017,8,873","journal-title":"Front Immunol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/ni.2474","volume":"14","author":"Mishra B.B.","year":"2013","unstructured":"Mishra B.B.; Rathinam V.A.K.; Martens G.W.; Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome\u2013dependent processing of IL-1&#x3B2;. Nat Immunol 2013,14(1),52-60","journal-title":"Nat Immunol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"216","DOI":"10.7326\/0003-4819-123-3-199508010-00009","volume":"123","author":"Gallin J.I.","year":"1995","unstructured":"Gallin J.I.; Farber J.M.; Holland S.M.; Nutman T.B.; Interferon-&#x3B3; in the management of infectious diseases. Ann Intern Med 1995,123(3),216-224","journal-title":"Ann Intern Med"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1186\/s12879-019-4526-x","volume":"19","author":"Payen D.","year":"2019","unstructured":"Payen D.; Faivre V.; Miatello J.; Multicentric experience with interferon gamma therapy in sepsis induced immuno-suppression. A case series. BMC Infect Dis 2019,19(1),931","journal-title":"BMC Infect Dis"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1001\/jama.2020.10245","volume":"324","author":"Marovich M.","year":"2020","unstructured":"Marovich M.; Mascola J.R.; Cohen M.S.; Monoclonal antibod-ies for prevention and treatment of COVID-19. JAMA 2020,324(2),131-132","journal-title":"JAMA"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"806568","DOI":"10.3389\/fphar.2022.806568","volume":"13","author":"Naik R.R.","year":"2022","unstructured":"Naik R.R.; Shakya A.K.; Aladwan S.M.; El-Tanani M.; Kinase inhibitors as potential therapeutic agents in the treatment of COVID-19. Front Pharmacol 2022,13,806568","journal-title":"Front Pharmacol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"bph.15182","DOI":"10.1111\/bph.15182","volume":"177","author":"Purvis GSD","year":"2020","unstructured":"Purvis GSD; Collino M; Aranda-Tavio H; Inhibition of Bruton\u2019s TK regulates macrophage NF\u2010&#x3BA;B and NLRP3 inflammasome activation in metabolic inflammation. Br J Pharmacol 2020,177(19),bph.15182","journal-title":"Br J Pharmacol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13075-018-1685-x","volume":"20","author":"Furuya M.Y.","year":"2018","unstructured":"Furuya M.Y.; Asano T.; Sumichika Y.; Tofacitinib inhib-its granulocyte\u2013macrophage colony-stimulating factor-induced NLRP3 inflammasome activation in human neutro-phils. Arthritis Res Ther 2018,20(1),196","journal-title":"Arthritis Res Ther"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.smrv.2004.05.002","volume":"9","author":"Arendt J.","year":"2005","unstructured":"Arendt J.; Skene D.J.; Melatonin as a chronobiotic. Sleep Med Rev 2005,9(1),25-39","journal-title":"Sleep Med Rev"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.smrv.2004.08.001","volume":"9","author":"Claustrat B.","year":"2005","unstructured":"Claustrat B.; Brun J.; Chazot G.; The basic physiology and pathophysiology of melatonin. Sleep Med Rev 2005,9(1),11-24","journal-title":"Sleep Med Rev"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/jpi.12360","volume":"61","author":"Reiter R.J.","year":"2016","unstructured":"Reiter R.J.; Mayo J.C.; Tan D.X.; Sainz R.M.; Alatorre-Jimenez M.; Qin L.; Melatonin as an antioxidant: Under promises but over delivers. J Pineal Res 2016,61(3),253-278","journal-title":"J Pineal Res"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40261-015-0368-5","volume":"36","author":"Andersen L.P.H.","year":"2016","unstructured":"Andersen L.P.H.; G&#xF6;genur I.; Rosenberg J.; The safety of melatonin in humans. Clin Drug Investig 2016,36(3),169-175","journal-title":"Clin Drug Investig"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.etp.2017.05.002","volume":"69","author":"Khaksar M.","year":"2017","unstructured":"Khaksar M.; Oryan A.; Sayyari M.; Rezabakhsh A.; Rahbar-ghazi R.; Protective effects of melatonin on long-term admin-istration of fluoxetine in rats. Exp Toxicol Pathol 2017,69(8),564-574","journal-title":"Exp Toxicol Pathol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12950-021-00269-5","volume":"18","author":"Rahbarghazi A.","year":"2021","unstructured":"Rahbarghazi A.; Siahkouhian M.; Rahbarghazi R.; Role of melatonin in the angiogenesis potential; highlights on the cardiovascular disease. J Inflamm 2021,18(1),4","journal-title":"J Inflamm"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10549-014-2962-2","volume":"145","author":"Hansen M.V.","year":"2014","unstructured":"Hansen M.V.; Andersen L.T.; Madsen M.T.; Effect of melatonin on depressive symptoms and anxiety in patients undergoing breast cancer surgery: A randomized, double-blind, placebo-controlled trial. Breast Cancer Res Treat 2014,145(3),683-695","journal-title":"Breast Cancer Res Treat"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/j.1600-079X.2012.00992.x","volume":"53","author":"de Matos Cavalcante A.G.","year":"2012","unstructured":"de Matos Cavalcante A.G.; de Bruin P.F.C.; de Bruin V.M.S.; Melatonin reduces lung oxidative stress in patients with chronic obstructive pulmonary disease: A randomized, dou-ble-blind, placebo-controlled study. J Pineal Res 2012,53(3),238-244","journal-title":"J Pineal Res"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1835195","DOI":"10.1155\/2017\/1835195","volume":"2017","author":"Favero G.","year":"2017","unstructured":"Favero G.; Franceschetti L.; Bonomini F.; Melatonin as an anti-inflammatory agent modulating inflammasome activa-tion. Int J Endocrinol 2017,2017,1835195","journal-title":"Int J Endocrinol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/jpi.12322","volume":"60","author":"Zhang Y.","year":"2016","unstructured":"Zhang Y.; Li X.; Grailer J.J.; Melatonin alleviates acute lung injury through inhibiting the NLRP3 inflammasome. J Pineal Res 2016,60(4),405-414","journal-title":"J Pineal Res"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"e12414","DOI":"10.1111\/jpi.12414","volume":"63","author":"Liu Z.","year":"2017","unstructured":"Liu Z.; Gan L.; Xu Y.; Melatonin alleviates inflam-masome-induced pyroptosis through inhibiting NF-&#x3BA;B\/GSDMD signal in mice adipose tissue. J Pineal Res 2017,63(1),e12414","journal-title":"J Pineal Res"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41413-020-0087-2","volume":"8","author":"Chen F.","year":"2020","unstructured":"Chen F.; Jiang G.; Liu H.; Melatonin alleviates interver-tebral disc degeneration by disrupting the IL-1&#x3B2;\/NF-&#x3BA;B-NLRP3 inflammasome positive feedback loop. Bone Res 2020,8(1),10","journal-title":"Bone Res"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"264","DOI":"10.32794\/mr11250061","volume":"3","author":"Hardeland R.","year":"2020","unstructured":"Hardeland R.; Tan D.X.; Protection by melatonin in respiratory diseases: Valuable information for the treatment of COVID-19. Melatonin Research 2020,3(3),264-275","journal-title":"Melatonin Research"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1186\/s13063-020-04737-w","volume":"21","author":"Ziaei A.","year":"2020","unstructured":"Ziaei A.; Davoodian P.; Dadvand H.; Evaluation of the efficacy and safety of melatonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials 2020,21(1),882","journal-title":"Trials"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1186\/s13063-020-04632-4","volume":"21","author":"Rodr&#xED;guez-Rubio M.","year":"2020","unstructured":"Rodr&#xED;guez-Rubio M.; Figueira J.C.; Acu&#xF1;a-Castroviejo D.; Borobia A.M.; Escames G.; de la Oliva P.; A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): A structured summary of a study proto-col for a randomized controlled trial. Trials 2020,21(1),699","journal-title":"Trials"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1186\/s13063-020-04436-6","volume":"21","author":"Garc&#xED;a I.G.","year":"2020","unstructured":"Garc&#xED;a I.G.; Rodriguez-Rubio M.; Mariblanca A.R.; A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial. Trials 2020,21(1),466","journal-title":"Trials"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"656-e1-656. e6","DOI":"10.1016\/j.jcrc.2010.03.006","volume":"25","author":"Srinivasan V","year":"2010","unstructured":"Srinivasan V; Pandi-Perumal SR; Spence DW; Melatonin in septic shock: Some recent concepts. J Critic Care 2010,25(4),656-e1-656. e6","journal-title":"J Critic Care"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"173530","DOI":"10.1016\/j.ejphar.2020.173530","volume":"887","author":"Sahebnasagh A.","year":"2020","unstructured":"Sahebnasagh A.; Saghafi F.; Avan R.; The prophylaxis and treatment potential of supplements for COVID-19. Eur J Pharmacol 2020,887,173530","journal-title":"Eur J Pharmacol"},{"key":"ref=97","first-page":"563","volume":"35","author":"Ma Y.","year":"2019","unstructured":"Ma Y.; Tang K.; Zhang C.; Advances in the role of mela-tonin in infectious diseases: A review. Chinese J Cell Mol Immunol 2019,35(6),563-568","journal-title":"Chinese J Cell Mol Immunol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s40263-019-00680-w","volume":"33","author":"Besag F.M.C.","year":"2019","unstructured":"Besag F.M.C.; Vasey M.J.; Lao K.S.J.; Wong I.C.K.; Adverse events associated with melatonin for the treatment of primary or secondary sleep disorders: A systematic review. CNS Drugs 2019,33(12),1167-1186","journal-title":"CNS Drugs"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/rheumatology\/kex453","volume":"57","author":"Slobodnick A.","year":"2018","unstructured":"Slobodnick A.; Shah B.; Krasnokutsky S.; Pillinger M.H.; Up-date on colchicine, 2017. Rheumatology 2018,57(Suppl. 1),i4-i11","journal-title":"Rheumatology"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","volume":"383","author":"Nidorf S.M.","year":"2020","unstructured":"Nidorf S.M.; Fiolet A.T.L.; Mosterd A.; Colchicine in patients with chronic coronary disease. N Engl J Med 2020,383(19),1838-1847","journal-title":"N Engl J Med"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1161\/CIRCULATIONAHA.120.050560","volume":"142","author":"Opstal T.S.J.","year":"2020","unstructured":"Opstal T.S.J.; Hoogeveen R.M.; Fiolet A.T.L.; Colchicine attenuates inflammation beyond the inflammasome in chronic coronary artery disease. Circulation 2020,142(20),1996-1998","journal-title":"Circulation"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2017.12.027","volume":"269","author":"Mart&#xED;nez G.J.","year":"2018","unstructured":"Mart&#xED;nez G.J.; Celermajer D.S.; Patel S.; The NLRP3 inflam-masome and the emerging role of colchicine to inhibit athero-sclerosis-associated inflammation. Atherosclerosis 2018,269,262-271","journal-title":"Atherosclerosis"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/med.20097","volume":"28","author":"Bhattacharyya B.","year":"2008","unstructured":"Bhattacharyya B.; Panda D.; Gupta S.; Banerjee M.; Anti-mitotic activity of colchicine and the structural basis for its in-teraction with tubulin. Med Res Rev 2008,28(1),155-183","journal-title":"Med Res Rev"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1172\/JCI118147","volume":"96","author":"Cronstein B.N.","year":"1995","unstructured":"Cronstein B.N.; Molad Y.; Reibman J.; Balakhane E.; Levin R.I.; Weissmann G.; Colchicine alters the quantitative and qualita-tive display of selectins on endothelial cells and neutrophils. J Clin Invest 1995,96(2),994-1002","journal-title":"J Clin Invest"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1111\/bcp.15149","volume":"88","author":"Poddighe D.","year":"2022","unstructured":"Poddighe D.; Romano M.; Garcia-Bournissen F.; Demirkaya E.; Conventional and novel therapeutic options in children with familial Mediterranean fever: A rare autoinflammatory disease. Br J Clin Pharmacol 2022,88(6),2484-2499","journal-title":"Br J Clin Pharmacol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"Martinon F.","year":"2006","unstructured":"Martinon F.; P&#xE9;trilli V.; Mayor A.; Tardivel A.; Tschopp J.; Gout-associated uric acid crystals activate the NALP3 in-flammasome. Nature 2006,440(7081),237-241","journal-title":"Nature"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/ni.3457","volume":"17","author":"Park Y.H.","year":"2016","unstructured":"Park Y.H.; Wood G.; Kastner D.L.; Chae J.J.; Pyrin inflam-masome activation and RhoA signaling in the autoinflamma-tory diseases FMF and HIDS. Nat Immunol 2016,17(8),914-921","journal-title":"Nat Immunol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/1074248413499972","volume":"19","author":"Nidorf S.M.","year":"2014","unstructured":"Nidorf S.M.; Eikelboom J.W.; Thompson P.L.; Targeting cho-lesterol crystal-induced inflammation for the secondary pre-vention of cardiovascular disease. J Cardiovasc Pharmacol Ther 2014,19(1),45-52","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"32587","DOI":"10.1038\/srep32587","volume":"6","author":"Otani K.","year":"2016","unstructured":"Otani K.; Watanabe T.; Shimada S.; Colchicine prevents NSAID-induced small intestinal injury by inhibiting activa-tion of the NLRP3 inflammasome. Sci Rep 2016,6(1),32587","journal-title":"Sci Rep"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/j.1476-5381.2011.01254.x","volume":"163","author":"Marques-da-Silva C.","year":"2011","unstructured":"Marques-da-Silva C.; Chaves M.M.; Castro N.G.; Coutinho-Silva R.; Guimaraes M.Z.P.; Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor-expressing cells: Implications for its therapeutic action. Br J Pharmacol 2011,163(5),912-926","journal-title":"Br J Pharmacol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"e0261358","DOI":"10.1371\/journal.pone.0261358","volume":"16","author":"Chiu L.","year":"2021","unstructured":"Chiu L.; Lo C.H.; Shen M.; Colchicine use in patients with COVID-19: A systematic review and meta-analysis. PLoS One 2021,16(12),e0261358","journal-title":"PLoS One"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ptr.7319","volume":"36","author":"Pourdowlat G.","year":"2022","unstructured":"Pourdowlat G.; Saghafi F.; Mozafari A.; Efficacy and safety of colchicine treatment in patients with COVID \u201019: A prospective, multicenter, randomized clinical trial. Phytother Res 2022,36(2),891-898","journal-title":"Phytother Res"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"e001455","DOI":"10.1136\/rmdopen-2020-001455","volume":"7","author":"Lopes M.I.","year":"2021","unstructured":"Lopes M.I.; Bonjorno L.P.; Giannini M.C.; Beneficial ef-fects of colchicine for moderate to severe COVID-19: A ran-domised, double-blinded, placebo-controlled clinical trial. RMD Open 2021,7(1),e001455","journal-title":"RMD Open"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666220906111550","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/208582\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666220906111550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T16:01:31Z","timestamp":1693670491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/208582\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":113,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867329666220906111550","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-01-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}